XLO Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
10.0M
-46.6%
18.7M
+47.8%
12.6M
-7.6%
13.7M
-28.2%
19.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
10.0M
-46.6%
18.7M
+47.8%
12.6M
-7.6%
13.7M
-28.2%
19.1M
Operating Expenses
21.7M
-2.0%
22.2M
-17.1%
26.8M
+4.9%
25.5M
+21.6%
21.0M
R&D
14.8M
+1.7%
14.6M
-26.6%
19.8M
+9.4%
18.1M
+26.5%
14.3M
SG&A
6.9M
-9.1%
7.6M
+10.0%
6.9M
-6.4%
7.4M
+10.9%
6.7M
Operating Income
-11749000
-236.6%
-3491000
+75.3%
-14112000
-19.2%
-11836000
-513.6%
-1929000
EBITDA
-11428000
-261.6%
-3160000
+77.0%
-13768000
-19.6%
-11513000
-624.5%
-1589000
Net Income
-5948000
+6.7%
-6373000
+33.1%
-9529000
-192.0%
10.4M
+163.6%
-16287000
EPS (Basic)
$-0.30
+9.1%
$-0.33
+43.1%
$-0.58
-161.1%
$0.95
+160.1%
$-1.58
EPS (Diluted)
$-0.30
+9.1%
$-0.33
+43.1%
$-0.58
-161.1%
$0.95
+160.1%
$-1.58
Shares (Diluted)
19.7M
+1.5%
19.4M
+18.7%
16.3M
+49.7%
10.9M
+6.1%
10.3M
Xilio Therapeutics (XLO) — Financials